When Gilead's hep C drugs hit the market, their older rivals went into a tailspin. Now, it's Gilead's time to suffer. The hep C market is once again proving a "flash in the pan," one analyst said Tuesday as he cut annual sales forecasts by $2 billion to $2.5 billion after 2017.
